Coagulation Cancer Testing & Interpretation

Added: Feb 02, 2017 10:13 am NOTICE OF INTENT TO AWARD NONCOMPETITIVE PROCUREMENT





Requisition No.: 648-17-3-066-0063 Date of Notice: 02/02/2017



Contracting Officer: DIANA CURL Closing Date: 02/11/2017



This notice will appear for 10 days from above date.

**************************************************************************************

Description of Supplies/Services:



The Department of Veterans Affairs, Portland VA Medical Center (PVAMC), requires services, non personal, for reference laboratory services with professional interpretation of test results performed in the reference lab, all in support of direct patient care. The estimated length of this contract will be a base period of four months, with 4 option years.

The Government intends to award this requirement noncompetitively to Oregon Health and Science University IAW FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The authority for restricting competition on this procurement is 41 U.S.C Code 3304(a), as implemented by FAR 6.302 for acquisitions of commercial items.

The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, coagulation and cancer testing and interpretation for the tests listed in the table below. Reference lab will provide the test results to Portland Pathology & Laboratory (PLMS), PVAMC.



Work will be performed in the Oregon Health & Science University (OHSU) Reference Laboratory,



The proposed contractor is Oregon Health & Science University, and the total estimated value of the proposed action is $8,278,300.00 over a five-year period with the base period beginning on 06-01-2017 and running to 09-30-2017. The base period is estimated at $636,648.80, and the four option years total $7,641,651.20.



































Description

CPT

Est. Quantity

0.5 Year

Est. Quantity

Full Year

Program

Molecular diagnosis: Cancer Interpretation and report

83912

67

134

Cancer Interpretation

Molecular diagnosis: Cancer Interpretation and report

83912

67

134

Cancer Interpretation

Molecular diagnosis: Cancer Interpretation and report

83912

66

132

Cancer Interpretation

Blood Smear peripheral Cancer Interpretation with report

85060

150

300

Cancer Interpretation

Bone marrow smear Cancer Interpretation, with or without differential cell count

85097

170

340

Cancer Interpretation

Cytopathology, concentration technique, smears and Cancer Interpretation

88108

175

350

Cancer Interpretation

flow cytometry, Cancer Interpretation; 2-8 markers

88187

150

300

Cancer Interpretation

flow cytometry, Cancer Interpretation; 9-15 markers

88188

150

300

Cancer Interpretation

flow cytometry, Cancer Interpretation; 16 or more markers

88189

150

300

Cancer Interpretation

Cytogenetics and molecular cytogenetics, Cancer Interpretation and report

88291

150

300

Cancer Interpretation

Level IV surgical pathology, gross and microscopic examination

88305

150

300

Cancer Interpretation

Special Stains, group II

88313

149

298

Cancer Interpretation

Special Stains, histochemical staining with frozen sections

88314

150

300

Cancer Interpretation

Determinative histochemistry or cytochemistry to identify enzyme constituents

88319

150

300

Cancer Interpretation

Consultation and report on referred slides prepared elsewhere

88321

162

324

Cancer Interpretation

immunocytochemistry (including immunoperoxidase) each antibody

88342

188

376

Cancer Interpretation

Immunoflourescent study, each antibody, direct method

88346

200

400

Cancer Interpretation

Electron microscopy, diagnostic

88348

200

400

Cancer Interpretation

Morphometric analysis, in situ hybridization

88368

200

400

Cancer Interpretation

Macroscopic examination, dissection, and preparation of tissue for non-microscopic analytical studies (nucleic acid-based molecular studies)

88387

200

400

Cancer Interpretation

ABL SEQ MOLE SEP BY CAP ELE

81403

70

140

Cancer Testing

Addl Karyotype simple

88280

75

150

Cancer Testing

ANTI-B2-GLYCOPROTIEN ICG

86146

70

140

Coagulation Testing

ANTICARDIOLIPIN IGG or IGM

86147

70

140

Coagulation Testing

ANTITHROMBIN ACTIVITY

85300

70

140

Coagulation Testing

APTT 1"1 MIX 0 MIN

85732

70.5

141

Coagulation Testing

APTT PLASMA 60 MIN

85730

70

140

Coagulation Testing

BCR/ABL FISH Probe

88271

68

136

Cancer Testing

BCR-ABL Nested PCR Assay

81208

70

140

Cancer Testing

BCR-ABL RNA Major Breakpoint

81206

70

140

Cancer Testing

BCR-ABL RNA Minor Breakpoint

81207

70

140

Cancer Testing

Bone Marrow Chromosome

88237

81.5

163

Cancer Testing

Butyrate Esterase Stain

88319

70

140

Cancer Testing

CNT 15-20 cells 2 karyotype

88262

70

140

Cancer Testing

DECALIFICATION

88311

70

140

Cancer Testing

DVV confirm ratio

85613

70

140

Coagulation Testing

DVVT

85613

70

140

Coagulation Testing

EOSINOPHILS Fish Probe

88271

70

140

Cancer Testing

FACTOR II ACTIVITY

85210

70

140

Coagulation Testing

FACTOR IX ACTIVITY

85250

70

140

Coagulation Testing

Factor V Activity

85220

70

140

Coagulation Testing

Factor V inhibitor

85335

70

140

Coagulation Testing

Factor VII Activity

85230

70

140

Coagulation Testing

FACTOR VIII COAG ACTIVITY

85240

70

140

Coagulation Testing

FACTOR VIII VWF AG

85246

70

140

Coagulation Testing

FACTOR X CHROMOGENIC

85260

70

140

Coagulation Testing

FACTOR XI ACTIVITY

85270

70

140

Coagulation Testing

FACTOR XII ACTIVITY

85280

70

140

Coagulation Testing

FACTOR XIII QUAL

85290

70

140

Coagulation Testing

Hem onc bld chromo

88237

70

140

Cancer Testing

HEPARIN EITHER STD/LMW

85520

70

140

Coagulation Testing

HEPARIN PLT AB LUMI AGG

86022

75

150

Coagulation Testing

HEXAGONAL PL APTT

85598

70.5

141

Coagulation Testing

Hormone Receptors, ER, PR, EA

88360

75

150

Cancer Testing

IMMUNOFLUORESCENCE (EA)

88346

20

40

Cancer Testing

IMMUNOHISTOCHEMISTRY

88342

55

110

Cancer Testing

IN SITU HYBRIDIZATION

88368

75

150

Cancer Testing

interphase 100-300 cells

88275

80

160

Cancer Testing

JAK2 V617F Qual Mut Analysis

81270

70

140

Cancer Testing

JAK2 V617F Quant Mut Analysis

81270

70

140

Cancer Testing

METHOTREXATE

80299

75

150

Cancer Testing

molecular probe

88271

70

140

Cancer Testing

MSI MULTIPLEX PCR

81301

75

150

Cancer Testing

MSI MULTIPLEX PCR 1ST 2

81301

75

150

Cancer Testing

MYELOPEROXIDASE STAIN

88319

67.5

135

Cancer Testing

PLATELET FACTOR 4 W/REFLEX TO HAL

86022

56.5

113

Coagulation Testing

Platelet Function Analysis

85576

56.5

113

Coagulation Testing

RETICULATED PLATELETS

85046

32.5

65

Cancer Testing

SPECIAL STAIN OTHER

88313

32.5

65

Cancer Testing

SUDAN BLACK B STAIN LEUKOCYTE

88313

32.5

65

Cancer Testing

SURFACE MARKER AB ADDL

88184

32.5

65

Cancer Testing

SURFACE MARKER AB FIRST

88185

32

64

Cancer Testing

T CELL QUANT (T,B AND NK)

86360

32.5

65

Cancer Testing

VONWILL/RAF

85245

56.5

113

Coagulation Testing



A review of the potential acquisition alternatives was performed taking into consideration previous acquisitions of a similar item or service, the impact of prior acquisitions on these alternatives, and related in-house efforts, which indicated that the best acquisition method was identified.



In-house resources, or the award of a new contract based on full and open competition after the exclusion of sources were both considered for this requirement. The PVAMC does not have the resources available to perform this service on their own, nor does it employ the required personnel to fill this need. As such, the facility requires testing and interpretation services from a reference laboratory that will be able to initiate specimen processing within 1 hour of specimen collection for all tests listed in the program Coagulation Testing, because coagulation and blood clotting disorders require immediate treatment and management. Patients are waiting for scheduled surgery or changes to medication doses.



There are several contractors that are capable of providing the required coagulation and cancer testing; however OHSU is the only contractor that could be found that is capable of providing this one hour testing start time requirement. There is a sky bridge that connects PVAMC with OHSU.



Delays in treatment and management of coagulation and blood clotting disorders are unacceptable for the prompt access of the VA, whereas immediate testing and resulting through a reference laboratory able to meet the 1 hour processing standard, furthers the goal of timely patient access. Delays in test results beyond 4-12 hours would typically result in canceled/delayed surgeries/treatments or serious negative consequences for patients with high risk factors (cancer, cardiovascular disease and serious health conditions). The expected turn-around time for coagulation tests results related to surgical procedures must be within 8 hours.



Competition was sought for this requirement by posting a sources sought notice to FedBizOpps and to GSA e-Buy on 11-03-2016 with a closing date of 11-10-2016. GSA lists five Medical Laboratories, four of which are large business, and one of which is a small business (Cedar Diagnostics).



The only businesses that could be found that showed any interest in this requirement was from the sources sought notice posted to GSA. Quest Diagnostics provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar Diagnostics also provided a capabilities statement, but stated they could not meet the testing start time of one hour after specimen collection. Cedar challenged the one-hour requirement, and stated that it is not required. However, it is the PVAMC laboratory s medical opinion that the one hour test start time for the coagulation and cancer tests is required and professionally disagrees with Cedar s claims.



PVAMC stated in a meeting with the Contract Specialist on 11-08-16 that they are standing behind the one-hour testing requirement.



A review of services available from the Committee for Purchase from people who are blind or severely disabled (AbilityOne) showed this service could not be provided by from this source at this time.



Research was conducted by searching the UNICOR website and reviewing the online FPI Schedule. UNICOR does not offer these services.



Research was conducted by reviewing the online WSNC and VISN contracting vehicle listings. There was no BPA available for OHSU.



Vets First does not apply. However, for market research purposes, VetBiz was reviewed using NAICS code 621511 for Washington and Oregon and revealed 6 matches. A review of their capabilities statements revealed that none can provide the specific services needed.



As described above, market research, in accordance with FAR Part 10, was conducted by posting a sources sought notice to FedBizOpps and to GSA on 11-03-16. The sources sought number is VA260-17-N-0033. A capability statement was requested in the notice. In the event new or unknown medical evidence changes the professional medical opinion of the PVAMC laboratory, regarding specimen testing beginning within one hour of collection, this requirement may be able to be competed if the specimen testing start time is extended from one hour to a time long enough for other laboratories located elsewhere in the country to be able to provide the required reference laboratory services.



PVAMC will continue to perform on going market research for other US labs acquiring the

capabilities to perform these unique and challenging tests.



Based upon the above information, there is a high level of confidence that no other qualified sources

exist.



Laboratory Corporation of America and Cedar Diagnostics hold a single award VISN 20 Blanket

Purchase Agreements (BPA) for reference lab testing. In the event the one hour testing start time is

changed, their BPAs could be used.



Other interested concerns having the ability to furnish these services shall submit a capabilities statement to the Contracting Officer no later than the closing date of this announcement. All submissions will be evaluated to determine if competitive opportunities exist. This is NOT an RFQ. This does represent the Government s only written notice of this procurement. All responsible sources may submit a response which, if timely received, must be considered by the agency.



The estimated/potential: $8,278,300.00

Place of Performance: Portland, OR



*************************************************************************************

*************************************************************************************



This notice and any resulting contract or order conforms to the requirements in place through

FAC 05-94/95 (effective 01-13-2017).



All questions regarding this procurement shall be in writing, and addressed to Diana Curl at diana.curl@va.gov no later than 02/11/2017.